BitFrontier Capital Holdings, Inc., operating as EVERMIND Holdings, Inc., has engaged Wellfleet Investments LLC to lead its capital formation strategy, marking a significant step in the company's methodical approach to creating shareholder value through disciplined turnaround execution. The veteran investment banking firm, established in New York in 1998, will support the company's efforts to raise capital through a structured two-phase approach that validates the company's strategic direction and governance reforms.
Wellfleet Investments LLC, a registered broker-dealer with the U.S. Securities and Exchange Commission that maintains membership with FINRA and SIPC, brings specialized expertise in structuring and placing financings for both private and public companies. The firm leverages deep relationships with family offices and institutional investors, providing BFCH with access to sophisticated capital sources that align with the company's repositioning toward cognitive health, functional wellness, and performance-driven innovation. Additional information about Wellfleet's capabilities and regulatory standing can be verified through FINRA BrokerCheck and the firm's comprehensive online presence.
The capital strategy will unfold through two distinct phases designed to systematically address corporate development needs. Phase I involves a seed raise of $150,000 to fund critical foundational work including legal and compliance review, modernization of the company's Charter and Bylaws, governance enhancements, and the formation of EVERMIND Labs. These proceeds will also support the finalization of the acquisition of ERApeutics, doing business as EVERMIND™ Beverage, along with PCAOB audit preparation, OTCQB uplisting readiness, and expanded investor relations efforts that will strengthen market confidence.
Phase II will involve a larger institutional raise ranging from $1.5 million to $2 million, contingent upon successful completion of Phase I and advancement to OTCQB status. These funds will be strategically deployed to acquire additional accretive assets, transition them into value-producing operations, and further scale the company's platform in the growing cognitive health market. This phased approach demonstrates the company's commitment to responsible capital allocation and measured growth, characteristics that resonate with institutional investors seeking structured turnarounds with clear milestones and governance frameworks.
Concurrently with these capital formation developments, BFCH has amended its Q2 report and 2024 management certification on OTC Markets to ensure all regulatory filings accurately reflect current management, capitalization, and strategic direction. This attention to compliance and transparency, combined with the engagement of a FINRA-registered investment banker, signals to the market that BFCH is executing a comprehensive repositioning strategy built on governance reform and compliance-focused capital formation that aligns with what smart capital seeks in early-stage investment opportunities.
